476660-18-1

Basic information

• Product Name: 3-(Quinolin-6-yl)propanal
• Synonyms: 3-(Quinolin-6-yl)propanal;6-Quinolinepropanal
• CAS NO: 476660-18-1
• Molecular Formula: C₁₂H₁₁NO
• Molecular Weight: 185.22184
• Mol File: 476660-18-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 328.4±17.0 °C(Predicted)
• Appearance: /
• Density: 1.133±0.06 g/cm3(Predicted)
• PKA: 5.05±0.10(Predicted)
• CAS DataBase Reference: 3-(Quinolin-6-yl)propanal(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Quinolin-6-yl)propanal(476660-18-1)
• EPA Substance Registry System: 3-(Quinolin-6-yl)propanal(476660-18-1)

Safety Data

• Hazardous Substances Data: 476660-18-1(Hazardous Substances Data)

Usage

General Description

3-(Quinolin-6-yl)propanal is a chemical compound with the molecular formula C13H11NO. It is a derivative of the quinoline family, which is known for its diverse biological activities. 3-(Quinolin-6-yl)propanal is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds due to its reactivity and functional groups. It possesses a quinoline ring structure with a propionaldehyde group, giving it potential for applications in drug discovery and organic chemistry. Its unique structure and reactivity make it a valuable building block for the development of new compounds with desired properties and functionalities in various fields.

Upstream product

• 5332-25-2 6-bromoquinoline 
• 1197377-26-6 6-(3,3-diethoxypropyl)quinoline 
• 107-18-6 allyl alcohol 
• 476660-16-9 3-quinolin-6-yl-propan-l-ol 

Downstream Products

• 476660-20-5 3-(quinolin-6-yl)propanoic acid 
• 1029714-85-9 2-chloro-3-quinolin-6-yl-propionaldehyde 

Relevant articles and documents

Deuterated Capmatinib compounds and uses thereof

The invention discloses deuterated Capmatinib compounds and uses thereof, in particular to compounds represented by formula (I) or optical isomers, pharmaceutically acceptable salts, hydrate or solvate thereof, wherein R1-R16 is independently selected fro

Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells

Sirtuins (SIRTs) catalyze the NAD+-dependent deacetylation of Nε-acetyl lysines on various protein substrates. SIRTs are interesting drug targets as they are considered to be related to important pathologies such as inflammation and aging-associated diseases. We have previously shown that chroman-4-ones act as potent and selective inhibitors of SIRT2. Herein we report novel chroman-4-one and chromone-based SIRT2 inhibitors containing various heterofunctionalities to improve pharmacokinetic properties. The compounds retained both high SIRT2 selectivity and potent inhibitory activity. Two compounds were tested for their antiproliferative effects in breast cancer (MCF-7) and lung carcinoma (A549) cell lines. Both compounds showed antiproliferative effects correlating with their SIRT2 inhibition potency. They also increased the acetylation level of α-tubulin, indicating that SIRT2 is likely to be the target in cancer cells. A binding mode of the inhibitors that is consistent with the SAR data was proposed based on a homology model of SIRT2.

SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME

The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.